Dose-Dependent Efficacy of Daratumumab as Monotherapy in Patients with Relapsed or Refractory Multiple Myeloma
|
|
- Marcus Patterson
- 6 years ago
- Views:
Transcription
1 Dose-Dependent Efficacy of Daratumumab as Monotherapy in Patients with Relapsed or Refractory Multiple Myeloma Henk Lokhorst, Jacob Laubach, Hareth Nahi, Torben Plesner, Peter Gimsing, Markus Hansson, Monique Minnema, Ulrik Lassen, Jakub Krejcik, Tahamtan Ahmadi, Steen Lisby, Linda Basse, Nikolai Brun, Paul Richardson University Medical Center Utrecht, Netherlands; Dana-Farber Cancer Institute, Boston, MA, USA; Karolinska Institutet, Stockholm, Sweden; Vejle Hospital, Denmark; Rigshospitalet, Copenhagen, Denmark; Lund University Hospital, Lund, Sweden; Janssen Research & Development, Raritan, NJ, USA; Genmab A/S, Copenhagen, Denmark;
2 Daratumumab Daratumumab (HuMax -CD38) is a fully human IgG1k monoclonal antibody with a broad spectrum of mechanisms of action including CDC, ADCC, ADCP, apoptosis induction and inhibition of enzymatic activity In development for treatment of patients with multiple myeloma Ongoing trials as monotherapy as well as in combination with Lenalidomide & Dexamethasone Fase III - With various velcade combinations
3 GEN501 - Monotherapy Part 1 (N=32): First-in-Human, dose escalation Results from part 1 a : Daratumumab well-tolerated Twelve patients dosed 4 24 mg/kg 5/12 (42%) achieved a PR as best response Part 2: Ongoing, cohort expansion Here we present preliminary data b from the first 50 patients. a Lokhorst et al. EHA 2013 abstract S576 b Data cut-off: May 02, 2014
4 Objectives Primary: Establish the safety profile of daratumumab as monotherapy in relapsed or relapsed and refractory multiple myeloma Secondary: Evaluate the efficacy of daratumumab Optimize premedication and infusion parameters for daratumumab Establish the optimal daratumumab dose Establish the PK profile for daratumumab
5 Trial Design Part 2 8 weekly doses, followed by 8 doses twice monthly and monthly dosing up to 24 months Cohort A Cohort B Cohort C Cohort D Dose (mg/kg) Pre-dose (10% of full dose, max 10 mg) Yes Yes No No Wash out (3 weeks between 1st and 2nd full infusion) No No No Yes Infusion time, 1 st full 4h 6h 6.5h 6.5h planned 2 nd full 3h15min 4h 4h 4h 3 rd full 3h15min 3h15min 3h15min 3h15min Infusion volume, ml 1 st full nd full rd full
6 Patient Characteristics Cohort A (N=16) Cohort B (N=8) Cohort C (N=6) Cohorts A+B+C (N=30) Cohort D (N=20) Dose (mg/kg) Age, years A (41-77) (38-74) (45-73) (38-77) 62 (51-76) Sex F/M% B 25/75 38/63 33/67 30/70 25/75 ECOG PS Prior therapy lines (numbers) Refractoriness, n (%) (0-2) (0-2) (0-1) (0-2) (0-1) (3-8) (3-10) (3-11) (3-11) (2-12) BORT C 19 (63) 8 (50) D LEN C 24 (80) 12(75) D BORT & LEN C 18 (60) 6 (38) D A: median (range) B: F/M = female/male, percent C: two patients have not been treated with Bortezomib or Lenalidomide D: one patient has not received Bortezomib or Lenalidomide and one patient is not evaluable.
7 Infusion Times : median (range) Cohort A Cohort B Cohort C Cohort A+B+C Cohort D Dose, mg/kg Pre-dose Yes Yes No Yes/No No Number of full infusions Duration of full infusions, hours (1-20) 1 st full 6.5 ( ) 2 nd full 4.2 ( ) 3 rd full 3.5 ( ) (1-21) 7.6 ( ) 5.9 ( ) 3.3 ( ) (3-18) 6.5 ( ) 4.0 ( ) 3.3 ( ) (1-21) 6.6 ( ) 4.2 ( ) 3.4 ( ) (1-15) 7.4 ( ) 6.7 ( ) 3.4 ( )
8 All AEs Grade 3/4 and SAEs per Dose Group 8mg/kg (N=30) 16mg/kg (N=20) Adverse event Grades 3/4 SAE Grades 3/4 SAE Total # of pts with AEs N (%) E 18 (60%) (40%) 17 6 (30%) 11 5 (25%) 6 Hematological Thrombocytopenia Anemia Neutropenia Lymphopenia 4 (13%) 6 1(3%)1 1 (3%) 2 1(5%)1 2(10%)4 2 (10%) 2 Non-hematological Hyperglycaemia Hypercalcaemia Hypokalemia Hypomagnesaemia Back Pain Muskuloskeletal Pain Osteoporotic fracture Pneumonia Bacteriemia Influenza RSV infection Pyrexia Chest Pain Face oedema Fatigue INR increased CPK increased Eye Swelling Limb Amputation 6th Nerve paralysis Renal Impairment Hypertension 2 (7%) 2 1 (3%) 2 1 (3%) 2 3 (10%) 4 1 (3%)1 1 (3%)1 1(3%)1 3 (10%) 4 1(3%)1 1(3%)1 1(3%)1 1 (5%) 2 1 (5%) 2 1 (5%) 1 1 (5%) 1 1 (5%) 1 1 (5%) 1 1 (5%) 2
9 Infusion Related Reactions (IRR) Dilution of the drug in 1000mL reduced the number of IRRs (cohorts C and D)
10 Best Change in Response Paraprotein (%) 100 IMWG Criteria (for measurable disease at baseline) Cohort A 8mg/kg Cohort B 8mg/kg Cohort C 8mg/kg Cohort D 16mg/kg mg/kg: in the 4 of 7 responders who had >=5% BM PCs at study entry, the BM PCs were cleared following treatment. 16 mg/kg: in the S4 Sof S7 Sresponders S US S F Swho S Shad S S>=5% S US FS BM SPCs S UUS at study S Uentry, FS US the UBM F UUUUUU 0 PCs were cleared following US treatment. S S S S S S S S- Serum, U Urine, F- FLC
11 Response rate (%) Response N=29 N=20 RR=10% RR=35% PR n=4 (20%) VGPR n=1 (5%) PR n=3 (10%) CR n=2 (10%) 8 mg/kg 16 mg/kg IMWG Criteria
12 BM PCs (%) Reduction in Bone Marrow Plasma Cells mg/kg 16mg/kg mg/kg: in the 4 of 7 responders who had >=5% BM PCs at study entry, the BM PCs were cleared following treatment. 16 mg/kg: in the 4 of 7 responders who had >=5% BM PCs at study entry, the BM PCs were cleared 30 following treatment Weeks All patients who achieved a PR or better at 16 mg/kg and who had bone marrow involvement cleared BMPC after daratumumab treatment (4/4 patients)
13 Progression-Free Survival 8 mg/kg 16 mg/kg Median PFS (weeks) Observed events 22 9 Censored observations 7 11 Follow-up Median (range) (weeks) 13.4 (0-47) 14.7 ( ) The median PFS estimate in the 16 mg/kg is rather immature. The current median PFS in the 16 mg/kg group is 23 weeks which is also the longest follow-up of any patient in this cohort.
14 Conclusions 1/2 Safety Daratumumab was well-tolerated No severe infusion-related reactions (IRRs) were seen All IRRs were grade 1 and 2 across all cohorts A,B,C (8mg/kg) and D (16mg/kg) Infusion times could be reduced to ~3.4 hours as of the 3 rd infusion
15 Conclusions 2/2 Efficacy The preliminary ORR (PR and better) showed a higher response of 35% in the 16 mg/kg cohort compared to 10% in the 8 mg/kg cohorts The response was deeper in the 16 mg/kg cohort in part 2 compared to the 8 mg/kg cohort and the higher dose cohorts. All patients who achieved a PR or better at 16 mg/kg and who had bone marrow involvement cleared BMPC after daratumumab treatment (4/4 patients)
16 Acknowledgments Special thanks to investigators, sub-investigators, research staff and patients and their families at the collaborating centers: Karolinska Institutet, Stockholm, Sweden Lund University Hospital, Lund, Sweden Rigshospitalet, Copenhagen, Denmark University Medical Center Utrecht, Utrecht, Netherlands Vejle Hospital, Vejle, Denmark Dana-Farber Cancer Institute, Boston MA, USA
ClinicalTrials.gov Identifier: NCT
Subcutaneous Delivery of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): PAVO, an Open-label, Multicenter, Dose Escalation Phase 1b Study Ajai Chari, 1 Hareth Nahi, 2 Maria-Victoria
More informationNew Agents in Multiple Myeloma. Saad Z Usmani, MD FACP
New Agents in Multiple Myeloma Saad Z Usmani, MD FACP The Context Advances in understanding myeloma biology has led to new therapeutic targets 100% 80% 60% TT3 OVERALL SURVIVAL Low-risk (42 / 363) Genomically
More informationClínica Universidad de Navarra-CIMA, IDISNA, Pamplona, Spain. ClinicalTrials.gov Identifiers: NCT and NCT
Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated With Daratumumab in Combination With Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone
More informationDaratumumab: Mechanism of Action
An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (D) Versus Lenalidomide and Dexamethasone () in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX* Meletios
More informationCity of Hope, Duarte, CA, USA; 11 Columbia University Medical Center, New York, NY, USA. 1
Open-label, Multicenter, Phase 1b Study of Daratumumab in Combination With Pomalidomide and Dexamethasone in Patients With 2 Lines of Prior Therapy and Refractory or Relapsed and Refractory Multiple Myeloma
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationDisclosures. Membership of Advisory Committees: Research Support/ PI: Celgene Corporation Millennium Pharmaceuticals Johnson & Johnson
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That
More informationElotuzumab is a humanized monoclonal antibody designed to treat multiple myeloma (MM)
A Phase 2 Study of in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/ Refractory Multiple Myeloma: Updated Results Paul G. Richardson, 1,2 Sundar Jagannath, 2,3 Philippe
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy: Updated Analysis of CASTOR Maria-Victoria
More informationDaratumumab: Uncovering a novel mechanism of action for an approved antibody therapy
Daratumumab: Uncovering a novel mechanism of action for an approved antibody therapy Dr. Kate Sasser, PhD Corporate VP, Translational Research December 14 th, 2017 CD38 is ubiquitously expressed in Myeloma
More informationDana-Farber Cancer Institute, Boston, MA, USA; 2. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; 3
The investigational agent MLN9708, an oral proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study
More informationAn Open-label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma
An Open-label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma Philippe Moreau, MD; Maria-Victoria Mateos, MD, PhD; Joan Bladé,MD; Lotfi
More informationPhase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial
Phase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial Jonathan L. Kaufman, Todd Zimmerman, Cara A. Rosenbaum, Anuj Mahindra,
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationH. Lee Moffitt Cancer Center and Research Institute, University of California, San Francisco & Tisch Cancer Institute, Mount Sinai School of Medicine
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study Rachid Baz, Thomas
More informationUniversity of Texas Southwestern, Dallas, TX, USA; 8 Vancouver General Hospital, Vancouver, BC, Canada; 9
First in Human Study with GSK285796, An Antibody Drug Conjugated to Microtubule-disrupting Agent Directed Against B-cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma: Results
More informationPomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma Lacy MQ et al. J Clin Oncol 2009;27(30):5008-14. Introduction A curative therapy for multiple myeloma (MM) does
More informationDARA Monotherapy Studies
Usmani, SZ. Blood. 26. http://dx.doi.org/.82/blood-26-3-752. Lokhorst HM, et al. N Engl J Med. 25;373(3):27-29. Lonial S, et al. Lancet. 25. I DARA Monotherapy Studies Baseline Characteristics Median (range)
More informationDisclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
More informationPhase 2 Study of Daratumumab (DARA) in Patients with 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma: MMY2002 (Sirius)*
Phase 2 Study of Daratumumab (DARA) in Patients with 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma: 54767414MMY2002 (Sirius)* Sagar Lonial, 1 Brendan Weiss, 2 Saad Usmani, 3 Seema Singhal,
More informationPhase 1, Multicenter, Open-label, Doseescalation,
Phase 1, Multicenter, Open-label, Doseescalation, Combination Study of Pomalidomide (POM), Marizomib (MRZ), and Dexamethasone (Lo-Dex) in Patients with Relapsed and Refractory Multiple Myeloma Study NPI-0052-107
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationDana-Farber Cancer Institute, Boston, MA, USA; 2 Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 3
Ibrutinib in Combination With Low-Dose Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma: Results From a Multicenter Phase 2 Trial Paul G. Richardson, MD 1 *, William
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationAt Fox Chase Cancer Centre during study participation
Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor Ixazomib at the Recommended Phase 3 Dose in Patients with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis
More informationMonoclonal antibodies and multiple myeloma Pr Philippe Moreau Nantes, France
Monoclonal antibodies and multiple myeloma Pr Philippe Moreau Nantes, France Disclosures Advisory boards and honoraria: Janssen, Takeda, Celgene, BMS, Novartis, Amgen Stockholder: no Rituximab + CHOP in
More informationA Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma
A Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma P.G. Richardson, 1 R. Schlossman, 1 N. Munshi, 1 D. Avigan, 2 S. Jagannath, 3 M. Alsina,
More informationSTUDY DESIGN. VMP 6-week cycles, total of 9 cycles. Figure 2. Alcyone study design. Countries housing study sites are shaded in gold.
TPS8608 A Randomized Open-label Study of Bortezomib, Melphalan, And Prednisone (VMP) Versus Daratumumab () Plus VMP in Patients With Previously Untreated Multiple Myeloma (MM) Who Are Ineligible for High-dose
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationDisclosures WOJCIECH JURCZAK
Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA
More informationJanssen Hematologic Malignancy Portfolio
Janssen Hematologic Malignancy Portfolio Recorded Webcast: Update for Analysts and Investors January 216 Oncology 1 Safe Harbor Statement This webcast contains "forward-looking statements" as defined in
More informationCost-effectiveness of Daratumumab (Darzalex ) for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.
Cost-effectiveness of Daratumumab (Darzalex ) for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma. The NCPE has issued a recommendation regarding the cost-effectiveness of
More informationEltanexor (KPT-8602), a Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple Myeloma
Eltanexor (KPT-8602), a Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple Myeloma R. Frank Cornell 1, Adriana Rossi 2, Rachid Baz 3, Craig C.
More informationInvestor Reception ASCO June 6, 2016
Investor Reception ASCO 216 June 6, 216 MorphoSys - ASCO - June 6, 216 1 Safe Harbor This presentation includes forward-looking statements. Actual results could differ materially from those included in
More informationFuture Strategies For Refractory Myeloma. Marc S. Raab
Future Strategies For Refractory Myeloma Marc S. Raab Multiple Myeloma Clonal proliferation of malignant plasma cells. excess bone marrow plasma cells monoclonal protein osteolytic bone lesions renal disease
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationTREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE PRESENTED BY: Pooja Chaukiyal MD Hematologist/Oncologist New York Oncology Hematology Albany, NY April 16, 2016 Background The prognosis for patients
More informationStudy Rationale. Reference: Chanan-Khan, A., et al., ASH 2010, Abstract#1962. Reference: Whiteman, K., et al, AACR, 2009, Abstract#2799
Phase I Study of Lorvotuzumab Mertansine (LM) in Combination with Lenalidomide and Dexamethasone in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM) Jesus Berdeja 1, Francisco
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationLong-term ixazomib maintenance is tolerable and improves depth of response following ixazomiblenalidomide-dexamethasone
Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomiblenalidomide-dexamethasone induction in patients with previously untreated multiple myeloma (MM): Phase 2 study
More information*Jagiellonian University, Kraków, Poland
Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin s Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study Wojciech Jurczak, *
More informationDARZALEX. daratumumab PRODUCT INFORMATION. DARZALEX (daratumumab) 20 mg/ml concentrate for solution for infusion. CAS Registry Number:
NAME OF THE MEDICINE DARZALEX daratumumab PRODUCT INFORMATION DARZALEX (daratumumab) 20 mg/ml concentrate for solution for infusion. CAS Registry Number: 945721-28-8. DESCRIPTION Daratumumab is an immunoglobulin
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationAbstract. Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA; 2 Hospital-12-de-Octubre, Madrid, Spain; 3
Daratumumab, Carfilzomib, and Dexamethasone (D-Kd) in Lenalidomiderefractory Patients with Relapsed Multiple Myeloma (MM): Subgroup Analysis of MMY11 Chari A, 1* Martinez-Lopez J, 2 Mateos M-V, 3 Bladé
More informationDARZALEX. daratumumab NEW ZEALAND DATA SHEET
1 PRODUCT NAME DARZALEX daratumumab NEW ZEALAND DATA SHEET DARZALEX (daratumumab) 20 mg/ml concentrate for solution for infusion. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 ml vial contains 100
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationOncology Highlights ASCO 2011 MULTIPLE MYELOMA
Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationFOR EU TRADE AND MEDICAL MEDIA ONLY
Media Inquiries: Natalie Buhl Mobile: +353 (0)85-744-6696 Email: nbuhl@its.jnj.com Investor Relations: Lesley Fishman Phone: +1-732-524-3922 New Data for Darzalex (daratumumab) Presented at ASH 2017 Show
More informationASCO 2017: Myeloma update
ASCO 2017: Myeloma update Jonathan L. Kaufman, MD Associate Professor Department of Hematology and Medical Oncology Winship Cancer Institute Emory University School of Medicine Daratumumab + KRd in Newly
More informationGli anticorpi monoclonali nel trattamento del mieloma multiplo recidivato/refrattario: anti CD38 e SLAMF7. Alessandro Corso
Gli anticorpi monoclonali nel trattamento del mieloma multiplo recidivato/refrattario: anti CD38 e SLAMF7 Alessandro Corso Immunological aspects of cancer chemotherapy Zitvogel et al. Nature Reviews Immunology,
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationPhase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Jatin J Shah, MD, Sheeba Thomas, MD, Donna Weber, MD, Michael Wang, MD, Raymond Alexanian, MD, Robert
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationMillennium Pharmaceuticals, Inc., Cambridge, MA; 11 Dana-Farber Cancer Institute, Boston, MA
Phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma Shaji K. Kumar,
More informationHorizon Scanning Centre November Pomalidomide for multiple myeloma third line SUMMARY NIHR HSC ID: 4436
Horizon Scanning Centre November 2012 Pomalidomide for multiple myeloma third line SUMMARY NIHR HSC ID: 4436 This briefing is based on information available at the time of research and a limited literature
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationManaging Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study
Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure
More informationNew IMWG Response Criteria
New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationConflict of Interest Disclosure Form
Conflict of Interest Disclosure Form NAME : Niels van de Donk MD-PhD AFFILIATION: University of California San Francisco. In accordance with the rules of the Health Care Inspectorate (IGZ), speakers are
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More informationManaging Major Adverse Events in Relapsed/Refractory Multiple Myeloma
Welcome to Managing Myeloma. I am Dr. Ajay Nooka. In today's presentation, I will discuss managing major adverse events in relapsed/refractory multiple myeloma. In this video, I will provide you with information
More informationFOR IMMEDIATE RELEASE
FOR IMMEDIATE RELEASE FOR UK MEDICAL AND TRADE MEDIA ONLY Takeda Presents Data from TOURMALINE-MM1 Study for Ixazomib, the First and Only Once-Weekly Oral Proteasome Inhibitor Studied in Phase III Clinical
More informationPhase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma Jatin J Shah, MD 1, Robert Z. Orlowski, MD, PhD 1, Raymond Alexanian, MD 1, Michael
More informationData featured as a Late-Breaking Abstract at ASH 2018 (Abstract #LBA-2)
Media Inquiries: Brian Kenney Phone: 1-215-620-0111 Satu Glawe Phone: +49 172 294 6264 Investor Relations: Christopher DelOrefice Phone: 1-732-524-2955 Lesley Fishman Phone: 1-732-524-3922 U.S. Medical
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationRegimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
Regimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone Constituents of Regimen: ixazomib, lenalidomide, dexamethasone Other Names of Regimen Constituents and Unique Ingredient Identifier
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationMayo Clinic, Rochester, Minnesota; 2 Tufts Medical Center, Boston, Massachusetts; 3
NEOD001 Demonstrates Organ Biomarker Responses in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction: Final Results From a Phase 1/2 Study Morie A. Gertz, 1 Raymond L. Comenzo, 2 Heather
More informationUpdates in Multiple Myeloma: 12 months in 10 minutes
Updates in Multiple Myeloma: 12 months in 10 minutes Aaron Rosenberg MD, MS Assistant Prof. Medicine UC Davis Comprehensive Cancer Center Division of Hematology and Oncology Outline Standard of care for
More informationPCI-32765DBL1002. Janssen Research & Development, Raritan, NJ, USA; 9 Janssen Research & Development, Belgrade, Serbia; 10
Phase 1b Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With CD20-Positive B-Cell Non-Hodgkin Lymphoma (NHL) Anas Younes, 1 Ian
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Bortezomib as first line induction prior to melphalan and autologous stem cell transplantation (ASCT) in untreated symptomatic multiple myeloma patients suitable
More informationCombining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study Jonathan Kaufman, Emory University Roberto Mina, Emory
More informationMechanism of action of anti CD38 antibodies
Mechanism of action of anti CD38 antibodies Tuna Mutis, MD, PhD Dept. of Hematology, VU University Medical Center Amsterdam, NL Conflict of Interest: T. Mutis Received research grants from Genmab & Janssen
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Daratumumab (Darzalex) for Multiple Myeloma October 5, 2017
pan-canadian Oncology Drug Review Final Clinical Guidance Report Daratumumab (Darzalex) for Multiple Myeloma October 5, 2017 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationBest of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationNovel treatment options for Waldenstrom Macroglobulinemia
Novel treatment options for Waldenstrom Macroglobulinemia Irene Ghobrial, MD Associate Professor of Medicine Harvard Medical School Dana Farber Cancer Institute Boston, MA Ghobrial et al, Lancet Oncol
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationNinlaro. (ixazomib) New Product Slideshow
Ninlaro (ixazomib) New Product Slideshow Introduction Brand name: Ninlaro Generic name: Ixazomib Pharmacological class: Proteasome inhibitor Strength and Formulation: 2.3mg, 3mg, 4mg; gel caps Manufacturer:
More informationBackground Information
What is Velcade (bortezomib)? Velcade (bortezomib) is a medicine used to treat a blood cancer known as multiple myeloma, and was the first of the treatments in the class of anti-cancer drugs known as proteasome
More informationprogression Monotherapy and in combination with lenalidomide and low-dose dexamethasone: every three weeks (total of 5 doses)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DARZALEX safely and effectively. See full prescribing information for DARZALEX. DARZALEX (daratumumab)
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationCLL - venetoclax. Peter Hillmen St James s University Hospital Leeds 10 th May 2016
CLL - venetoclax Peter Hillmen peter.hillmen@nhs.net St James s University Hospital Leeds 10 th May 2016 Pathophysiology of CLL: Proliferation vs Apoptosis Proliferation Apoptosis Ki-67 Expression Bcl-2
More informationNASDAQ: TGTX Jefferies Healthcare Conference June 2015
NASDAQ: TGTX Jefferies Healthcare Conference June 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationTolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced CLL and NHL
Tolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced and NHL Loretta Nastoupil, MD 1, Matthew A. Lunning, DO 2, Julie
More informationDuvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia
Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia Susan M. O Brien 1, Manish R. Patel 2,3, Brad Kahl 4, Steven Horwitz 5,
More information